Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults With Cancer
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults With Cancer
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
UCLA
mi
from
Los Angeles, CA
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center Research Institute
mi
from
Fairway, KA
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center Research Institute
mi
from
Fairway, KA
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Duke Cancer Center
mi
from
Durham, NC
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Saint Francis Cancer Center
mi
from
Greenville, SC
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Saint Francis Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Princess Margaret
mi
from
Toronto,
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Princess Margaret
mi
from
Toronto,
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated:  12/31/1969
Universitätsklinikum der Johann Wolfgang Goethe Universität
mi
from
Frankfurt,
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia
Status: Enrolling
Updated: 12/31/1969
Universitätsklinikum der Johann Wolfgang Goethe Universität
mi
from
Frankfurt,
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Florida College of Medicine
mi
from
Gainesville, FL
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Florida College of Medicine
mi
from
Gainesville, FL
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Blood and Marrow Transplant Program at Northside Hospital
mi
from
Atlanta, GA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Blood and Marrow Transplant Program at Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Hospital
mi
from
Kansas City, KA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Hospital
mi
from
Kansas City, KA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Dana Farber Cancer Institute/Brigham & Women's
mi
from
Boston, MA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Dana Farber Cancer Institute/Brigham & Women's
mi
from
Boston, MA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Dana Farber Cancer Institute/Massachusetts General Hospital
mi
from
Boston, MA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Dana Farber Cancer Institute/Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Ohio State, Arthur G. James Cancer Hospital
mi
from
Columbus, OH
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Ohio State, Arthur G. James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University/MCV Hospitals
mi
from
Richmond, VA
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University/MCV Hospitals
mi
from
Richmond, VA
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical Center - New York Presbyterian
mi
from
New York, NY
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical Center - New York Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials